JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Price:
1.82 HKD
-1.09%
Updated:
May 9, 2024
P/E
Price to Earnings
Price to Earnings
-0.9
Current
-2
Median
26.8
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-0.9
Market Cap
/
750.6m
Net Income
-768m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
750.6m HKD | -0.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 58.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 43.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 29.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 27.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 36 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 167.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | -7.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32B USD | 27.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 75.3 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-1.1
2-Years Forward
P/E
-1.3
3-Years Forward
P/E
-2
You don't have any saved screeners yet
